120. Hereditary dystonia
25 clinical trials,   22 drugs   (DrugBank: 4 drugs),   2 drug target genes,   2 drug target pathways

Searched query = "Hereditary dystonia", "DYT1 dystonia", "DYT2 dystonia", "DYT3 dystonia", "X-linked dystonia-parkinsonism", "Lubag", "DYT4 dystonia", "DYT5 dystonia", ... show all
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03726996
(ClinicalTrials.gov)
January 14, 201929/10/2018Desipramine in Infantile Neuroaxonal Dystrophy (INAD).Novel Off-label Use of Desipramine in Infantile Neuroaxonal Dystrophy: Targeting the Sphingolipid Metabolism Pathway to Reduce Accumulation of Ceramide.Infantile Neuroaxonal DystrophyDrug: DesipramineDuke UniversityNULLTerminated3 Years17 YearsAll4Phase 4United States